Compare Ginkgo Bioworks Holdings Inc (DNA) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Krispy Kreme Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.91 (market cap $763.64M), while Krispy Kreme Inc trades at $3.01 (market cap $521.37M). The key difference: Ginkgo Bioworks Holdings Inc is the larger of the two by market cap, and Krispy Kreme Inc pays a 3.47% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Krispy Kreme Inc for 45 Days on average.
| DNA | DNUT | |
|---|---|---|
Market Cap | $763.64M | $521.37M |
Volume | 3,204,177 | 2,293,015 |
Sector | Health | Consumer Staples |
52-Week High | $15.83 | $4.70 |
52-Week Low | $5.48 | $2.87 |
Typical Hold Time | 7 Days | 45 Days |
Enterprise Value | $865.59M | $1.76B |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Krispy Kreme (DNUT) trades at $2.92, down 3.31% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $515.77M in 2025, with a negative net income margin of -33.88%, though revenue remains stable at $1.52B. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, alongside seasonal product launches like the Pokémon doughnut collection.
The outlook is mixed; analyst consensus leans buy (50%) with a low P/S of 0.34 offering value, but profitability challenges and legal overhangs pose significant risks. Cash flow improved in 2025, yet high debt and negative ROE of -14.43% demand caution for stock investors seeking turnaround potential amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
